-18.8%
PYPL vs MRNA
+511.3%
-530.1%
-48.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -3.0% | -2.2% | -0.8% | -3.0% |
| 7D | +2.7% | +5.5% | -2.8% | +2.6% |
| 30D | -4.9% | +158.7% | -163.6% | -8.7% |
| 3M | +28.9% | +182.1% | -153.2% | +21.9% |
| 6M | +18.2% | +151.8% | -133.6% | +13.0% |
| YTD | -5.0% | +393.6% | -398.6% | -15.4% |
| 1Y | -18.8% | +499.5% | -518.3% | -29.8% |
| All | -18.8% | +511.3% | -530.1% | -29.8% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling